News und Analysen
![Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua™](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua™
Novocure (NASDAQ: NVCR) today announced that over 100 physicians from more than 50 cancer treatment centers in the U.S. are now certified to prescribe Optune Lua, which is approved for the
![NanoString to Release Second Quarter 2020 Financial Results and Host Conference Call on Monday, August 10, 2020](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
NanoString to Release Second Quarter 2020 Financial Results and Host Conference Call on Monday, August 10, 2020
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will release second quarter 2020
![VALBIOTIS: Authorization to Launch the International Phase II/III REVERSE-IT Clinical Study on TOTUM-63, to Reduce Type 2 Diabetes Risk Factors](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
VALBIOTIS: Authorization to Launch the International Phase II/III REVERSE-IT Clinical Study on TOTUM-63, to Reduce Type 2 Diabetes Risk Factors
Regulatory News:
VALBIOTIS (FR0013254851 - ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation, for preventing and combating metabolic diseases
![EOS imaging: Availability of the 2019 Annual Financial Report in English](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
EOS imaging: Availability of the 2019 Annual Financial Report in English
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning
![LivaNova Announces Publication Detailing the Design of the RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
LivaNova Announces Publication Detailing the Design of the RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a publication in Contemporary Clinical Trials1, which details the design for “A Prospective
![Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer
Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients
![Veeva Vault Helps VentilatorChallengeUK Speed Production of More Than 13,000 Ventilators for COVID-19](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Veeva Vault Helps VentilatorChallengeUK Speed Production of More Than 13,000 Ventilators for COVID-19
In an effort to help overcome the shortage of ventilators during COVID-19, Veeva Systems (NYSE: VEEV) today announced that VentilatorChallengeUK used Veeva Vault QMS to accelerate ventilator
![STAAR Surgical Introduces EVO Viva™ Presbyopia Correcting Lens – See Young Again!](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
STAAR Surgical Introduces EVO Viva™ Presbyopia Correcting Lens – See Young Again!
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that EVO Viva™, STAAR’s
![Otonomy: Tinnitus-Studie liefert glänzende Ergebnisse!](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Otonomy: Tinnitus-Studie liefert glänzende Ergebnisse!
Starke Tinnitus-Daten schicken die Aktie von Otonomy (WKN: A119VZ) nachbörslich in die Höhe. Im No Brainer Club reißt die Erfolgsserie nicht ab. Wie geht es jetzt weiter?
Mit der Aktie von Otonomy
![Quidel Announces Preliminary Revenue for Second Quarter 2020](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Quidel Announces Preliminary Revenue for Second Quarter 2020
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects
![Patrick F. Williams Appointed Chief Financial Officer of STAAR Surgical](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Patrick F. Williams Appointed Chief Financial Officer of STAAR Surgical
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that Patrick F. Williams has
![Sensorion Appoints Dr Edwin Moses, Former Ablynx CEO, as Chairman of the Board](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Sensorion Appoints Dr Edwin Moses, Former Ablynx CEO, as Chairman of the Board
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering, clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
![GenSight Biologics Reports Sustained Efficacy and Safety Among LHON Patients Three Years After LUMEVOQ® Treatment](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
GenSight Biologics Reports Sustained Efficacy and Safety Among LHON Patients Three Years After LUMEVOQ® Treatment
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for
![Paion: Die US-Zulassung ist da!](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Paion: Die US-Zulassung ist da!
Die Paion AG (WKN: A0B65S) kann den aus kommerzieller Sicht wohl wichtigsten Meilenstein ihrer Unternehmensgeschichte feiern: Exklusiven SD-Informationen zufolge wurde Paions potenzieller
![Simulations Plus Sets Date for 3rd Quarter 2020 Earnings Release and Conference Call](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Simulations Plus Sets Date for 3rd Quarter 2020 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP) announced today that it expects to file its quarterly report on Form 10-Q for the third quarter of its 2020 fiscal year, the period ended May 31, 2020, on
![Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine
![Ipsen presents Phase I/II clinical data evaluating liposomal irinotecan (Onivyde®) as an investigational first-line combination treatment for metastatic pancreatic cancer at the ESMO World Congress on Gastrointestinal Cancer](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Ipsen presents Phase I/II clinical data evaluating liposomal irinotecan (Onivyde®) as an investigational first-line combination treatment for metastatic pancreatic cancer at the ESMO World Congress on Gastrointestinal Cancer
Ipsen (Euronext: IPN; ADR: IPSEY), today announced the primary analysis of the Phase I/II study evaluating the investigational use of irinotecan liposome injection (Onivyde®) in combination with
![Lantheus Holdings to Showcase the Potential of PyL™ Imaging Agent at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Lantheus Holdings to Showcase the Potential of PyL™ Imaging Agent at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture
![Novocure to Report Second Quarter 2020 Financial Results](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Novocure to Report Second Quarter 2020 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2020 on Thursday, July 30, 2020, before the U.S. financial markets open. Novocure’s management
![Lysogene Announces a Research Collaboration With the Weizmann Institute of Science](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Lysogene Announces a Research Collaboration With the Weizmann Institute of Science
Regulatory News:
Lysogene (Paris:LYS)(FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that the company has entered
![IMV maintains the remainder of its At-the-Market Facility under its new Base Shelf Prospectus](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
IMV maintains the remainder of its At-the-Market Facility under its new Base Shelf Prospectus
IMV Inc. (“IMV” or the “Company”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company, today announced that in order to maintain the remainder of its at-the-market facility
![Premier Inc. Calls for National Stockpiling Standards to Prevent Redundant Efforts, Next Wave of Product Shortages](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Premier Inc. Calls for National Stockpiling Standards to Prevent Redundant Efforts, Next Wave of Product Shortages
Nearly 90 percent of healthcare providers are contributing to stockpiles of critical medical supplies and drugs intended to last as long as 90 days, according to a recent survey conducted by
![QIAGEN Shareholders Approve All Agenda Items Related to Acquisition by Thermo Fisher Scientific at Annual General Meeting](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
QIAGEN Shareholders Approve All Agenda Items Related to Acquisition by Thermo Fisher Scientific at Annual General Meeting
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced that its shareholders today approved all agenda items at the Company’s Annual General Meeting related to the proposed voluntary
![QIAGEN-Aktionäre stimmen bei Jahreshauptversammlung allen Beschlussvorschlägen im Zusammenhang mit der Übernahme durch Thermo Fisher Scientific zu](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
QIAGEN-Aktionäre stimmen bei Jahreshauptversammlung allen Beschlussvorschlägen im Zusammenhang mit der Übernahme durch Thermo Fisher Scientific zu
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab bekannt, dass die Aktionäre heute auf der Jahreshauptversammlung des Unternehmens allen Beschlussvorschlägen im Zusammenhang mit dem
![Dexcom Schedules Second Quarter 2020 Earnings Release and Conference Call for July 28, 2020 at 4:30 p.m. Eastern Time](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Dexcom Schedules Second Quarter 2020 Earnings Release and Conference Call for July 28, 2020 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2020 financial results after market close on Tuesday, July 28, 2020. Management will hold a conference call to